
What smart money is saying about Charles River Laboratories International, Inc.
3 funds in our archive have pitched Charles River Laboratories International, Inc. — most recently Ariel Mid Cap Value in December 2025.
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Fund coverage · 3 theses
- Ariel Mid Cap ValueDecember 2025
Charles River Laboratories is a leading outsourced drug development provider with resilient demand, diversified growth in areas like cell and gene therapy, and pricing power supporting long-term growth.
Read the full thesis - Harris Oakmark Concentrated StrategyJune 2025
Charles River Labs is a leading provider of preclinical research services with a strong competitive advantage, poised for growth despite current challenges, making it an attractive investment opportunity.
Read the full thesis - Upslope Capital ManagementDecember 2024
Charles River’s strong market position and improving fundamentals suggest potential upside as the biotech cycle turns
Read the full thesis
Read every full thesis on Charles River Laboratories International, Inc.
Unlock all 3 theses — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→